Key facts
- OxSonics Therapeutics’s last known valuation is $34.6M (Jul 2020).
- It has raised $30.2M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Innovate UK, University of Oxford, Perivoli Innovations, Anjost Investment, Winton Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for OxSonics Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for OxSonics Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OxSonics Therapeutics
Operator of a therapeutics platform intended to develop an anti-cancer therapy to improve the delivery of agents to tumors by disrupting their structure. The company's platform combines particles that are co-administered independently with a drug and actively manages the delivery of oncology drugs into solid tumors, and requires no drug reformulation, enabling healthcare providers to create a localized pumping effect that increases the delivery and penetration of the therapeutics throughout the tumor.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2013
- Employees
- 15
- Website
- oxsonics.com/
- Ownership
- Privately Held (backing)
OxSonics Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OxSonics Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OxSonics Therapeutics in its N-PORT filings yet. We sweep new filings monthly.